88 related articles for article (PubMed ID: 27022837)
1. Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Peng Y; Yu W; Li E; Kang J; Wang Y; Yang Q; Liu B; Zhang J; Li L; Wu J; Jiang J; Wang Q; Chang J
J Med Chem; 2016 Apr; 59(8):3661-70. PubMed ID: 27022837
[TBL] [Abstract][Full Text] [Related]
2. Studies directed toward the asialoglycoprotein receptor mediated delivery of 5-fluoro-2'-deoxyuridine for hepatocellular carcinoma.
Rico L; Østergaard ME; Bell M; Seth PP; Hanessian S
Bioorg Med Chem Lett; 2018 Aug; 28(15):2652-2654. PubMed ID: 30042045
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma.
Boyer SH; Sun Z; Jiang H; Esterbrook J; Gómez-Galeno JE; Craigo W; Reddy KR; Ugarkar BG; MacKenna DA; Erion MD
J Med Chem; 2006 Dec; 49(26):7711-20. PubMed ID: 17181153
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
Cheraghali AM; Kumar R; Knaus EE; Wiebe LI
Drug Metab Dispos; 1995 Feb; 23(2):223-6. PubMed ID: 7736915
[TBL] [Abstract][Full Text] [Related]
5. The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Supersaxo A; Rubas W; Hartmann HR; Schott H; Hengartner H; Schwendener RA
J Microencapsul; 1988; 5(1):1-11. PubMed ID: 2974073
[TBL] [Abstract][Full Text] [Related]
6. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
[TBL] [Abstract][Full Text] [Related]
7. In vivo distribution and antitumour activity of liposomal 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine.
Van Borssum Waalkes M; Fichtner I; Dontje B; Lemm M; Becker M; Arndt D; Scherphof GL
J Microencapsul; 1992; 9(3):335-46. PubMed ID: 1403484
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a novel β-D-2'-deoxy-2'-α-fluoro-2'-β-C-(fluoromethyl)uridine phosphoramidate prodrug for the treatment of hepatitis C virus infection.
Li E; Wang Y; Yu W; Lv Z; Peng Y; Liu B; Li S; Ho W; Wang Q; Li H; Chang J
Eur J Med Chem; 2018 Jan; 143():107-113. PubMed ID: 29172078
[TBL] [Abstract][Full Text] [Related]
10. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
11. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
12. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization using docetaxel-loaded phytantriol cubic phase precursor for the treatment of hepatocellular carcinoma.
Han K; Wang Z; Peng X; Chen B; Wen X; Dong Y; Wu C
J Pharm Sci; 2011 Jun; 100(6):2240-7. PubMed ID: 21491445
[TBL] [Abstract][Full Text] [Related]
14. Conjugation of 5-fluoro-2'-deoxyuridine with lactosaminated poly-l-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas.
Di Stefano G; Busi C; Derenzini M; Trerè D; Fiume L
Ital J Gastroenterol Hepatol; 1998 Apr; 30(2):173-7. PubMed ID: 9675653
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Dang Q; Liu Y; Cashion DK; Kasibhatla SR; Jiang T; Taplin F; Jacintho JD; Li H; Sun Z; Fan Y; DaRe J; Tian F; Li W; Gibson T; Lemus R; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2011 Jan; 54(1):153-65. PubMed ID: 21126019
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of 5-ethyl-2'-deoxyuridine and its 5,6-dihydro prodrugs in murine lung and its potential clinical application.
Cheraghali AM; Morin KW; Kumar R; Knaus EE; Wiebe LI
J Pharm Pharmacol; 1995 Jul; 47(7):595-600. PubMed ID: 8568628
[TBL] [Abstract][Full Text] [Related]
17. Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid tumors.
Infante JR; Benhadji KA; Dy GK; Fetterly G; Ma WW; Bendell J; Callies S; Adjei AA
Invest New Drugs; 2015 Apr; 33(2):432-9. PubMed ID: 25640850
[TBL] [Abstract][Full Text] [Related]
18. pH-Sensitive mesoporous silica nanoparticles anticancer prodrugs for sustained release of ursolic acid and the enhanced anti-cancer efficacy for hepatocellular carcinoma cancer.
Li T; Chen X; Liu Y; Fan L; Lin L; Xu Y; Chen S; Shao J
Eur J Pharm Sci; 2017 Jan; 96():456-463. PubMed ID: 27771513
[TBL] [Abstract][Full Text] [Related]
19. The effect of YNK-01 (an oral prodrug of cytarabine) on hepatocellular carcinoma.
Suto T; Miyazawa J; Watanabe Y; Suto K; Yoshida Y; Sakata Y
Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-122-S6-129. PubMed ID: 9151927
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biodistribution of [4-14C]-5-bromo-6-methoxy-5,6-dihydro-prodrug derivatives of 5-ethyl-2'-deoxyuridine.
Cheraghali AM; Morin KW; Kumar R; Knaus EE; Wiebe LI
Drug Des Discov; 1994 Jul; 12(1):53-61. PubMed ID: 7578807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
